Next Article in Journal
Fetal High-Density Lipoproteins: Current Knowledge on Particle Metabolism, Composition and Function in Health and Disease
Next Article in Special Issue
Leukotriene B4 Receptors Are Necessary for the Stimulation of NLRP3 Inflammasome and IL-1β Synthesis in Neutrophil-Dominant Asthmatic Airway Inflammation
Previous Article in Journal
MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer
Review

Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab

Pneumology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Hiroshi Wakao
Biomedicines 2021, 9(4), 348; https://doi.org/10.3390/biomedicines9040348
Received: 13 March 2021 / Revised: 26 March 2021 / Accepted: 26 March 2021 / Published: 30 March 2021
(This article belongs to the Special Issue Molecular Targets for Biological Therapies of Severe Asthma)
Viral respiratory infections are recognized risk factors for the loss of control of allergic asthma and the induction of exacerbations, both in adults and children. Severe asthma is more susceptible to virus-induced asthma exacerbations, especially in the presence of high IgE levels. In the course of immune responses to viruses, an initial activation of innate immunity typically occurs and the production of type I and III interferons is essential in the control of viral spread. However, the Th2 inflammatory environment still appears to be protective against viral infections in general and in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections as well. As for now, literature data, although extremely limited and preliminary, show that severe asthma patients treated with biologics don’t have an increased risk of SARS-CoV-2 infection or progression to severe forms compared to the non-asthmatic population. Omalizumab, an anti-IgE monoclonal antibody, exerts a profound cellular effect, which can stabilize the effector cells, and is becoming much more efficient from the point of view of innate immunity in contrasting respiratory viral infections. In addition to the antiviral effect, clinical efficacy and safety of this biological allow a great improvement in the management of asthma. View Full-Text
Keywords: viral respiratory infections; severe asthma; immune response; biologicals; omalizumab viral respiratory infections; severe asthma; immune response; biologicals; omalizumab
Show Figures

Figure 1

MDPI and ACS Style

Menzella, F.; Ghidoni, G.; Galeone, C.; Capobelli, S.; Scelfo, C.; Facciolongo, N.C. Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab. Biomedicines 2021, 9, 348. https://doi.org/10.3390/biomedicines9040348

AMA Style

Menzella F, Ghidoni G, Galeone C, Capobelli S, Scelfo C, Facciolongo NC. Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab. Biomedicines. 2021; 9(4):348. https://doi.org/10.3390/biomedicines9040348

Chicago/Turabian Style

Menzella, Francesco; Ghidoni, Giulia; Galeone, Carla; Capobelli, Silvia; Scelfo, Chiara; Facciolongo, Nicola C. 2021. "Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab" Biomedicines 9, no. 4: 348. https://doi.org/10.3390/biomedicines9040348

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop